Endothelin News and Research RSS Feed - Endothelin News and Research

Endothelins are proteins that constrict blood vessels and raise blood pressure. They are normally kept in balance by other mechanisms, but when they are over-expressed, they contribute to high blood pressure (hypertension) and heart disease.
Researchers call for earlier PAH diagnosis and treatment

Researchers call for earlier PAH diagnosis and treatment

A study has found that treatment of pulmonary arterial hypertension in patients younger than 55 years significantly improves their performance on the 6-minute walk test. [More]
Early decline in 6MWT distance predicts PAH worsening

Early decline in 6MWT distance predicts PAH worsening

Research shows that an early decline in 6-minute walk test distance can predict worsening of disease in patients with pulmonary arterial hypertension. [More]
Selten Pharma's SPI-026 granted FDA Orphan Drug Designation for treatment of PAH

Selten Pharma's SPI-026 granted FDA Orphan Drug Designation for treatment of PAH

Selten Pharma, Inc., a privatively held biopharmaceutical company focused on the development and commercialization of therapies for the treatment of rare diseases, announced today that its lead compound tacrolimus (SPI-026) has been granted Orphan Drug Designation by the U.S. Food & Drug Administration for the treatment of pulmonary arterial hypertension (PAH). [More]
UT Southwestern neuroscientists identify key brain cells that control circadian rhythms

UT Southwestern neuroscientists identify key brain cells that control circadian rhythms

UT Southwestern Medical Center neuroscientists have identified key cells within the brain that are critical for determining circadian rhythms, the 24-hour processes that control sleep and wake cycles, as well as other important body functions such as hormone production, metabolism, and blood pressure. [More]
Endothelin gene expression linked to vision loss in premature babies

Endothelin gene expression linked to vision loss in premature babies

A gene known to play a major role in constricting blood vessels also appears to be a major player in the aberrant blood vessel growth that can destroy the vision of premature babies. [More]
Vascular receptor autoantibodies implicated in SSc-PAH

Vascular receptor autoantibodies implicated in SSc-PAH

medwireNews: Autoantibodies to endothelin receptor type A and angiotensin receptor type-1 predict the development of, and mortality from, systemic sclerosis-associated pulmonary arterial hypertension, research suggests. [More]
Targeted treatments may improve idiopathic PAH survival

Targeted treatments may improve idiopathic PAH survival

Patients with idiopathic pulmonary arterial hypertension may live longer if they are given targeted treatments than if they receive conventional management, researchers suggest. [More]
CHEST guideline released for PAH

CHEST guideline released for PAH

An updated CHEST guideline for treating pulmonary arterial hypertension provides some evidence-based recommendations but also highlights many evidence gaps. [More]
Olive oil supplements may counteract adverse cardiovascular effects of exposure to air pollution

Olive oil supplements may counteract adverse cardiovascular effects of exposure to air pollution

Taking olive oil supplements may counteract some of the adverse cardiovascular effects of exposure to air pollution, according to a new study presented at the 2014 American Thoracic Society International Conference. [More]
Olive oil supplements may counteract adverse cardiovascular effects of air pollution

Olive oil supplements may counteract adverse cardiovascular effects of air pollution

Taking olive oil supplements may counteract some of the adverse cardiovascular effects of exposure to air pollution, according to a new study presented at the 2014 American Thoracic Society International Conference. [More]
Ambrisentan cleared for use with phenprocoumon

Ambrisentan cleared for use with phenprocoumon

Starting treatment with ambrisentan does not necessitate adjusting the dose of the oral anticoagulant phenprocoumon in patients with pulmonary hypertension who require both medications, report researchers. [More]
Meta-analysis links signalling pathways to bipolar disorder

Meta-analysis links signalling pathways to bipolar disorder

A meta-analysis of genome-wide association studies has identified six biological pathways that may be involved in the genetic predisposition to develop bipolar disorder. [More]
Bayer’s Adempas now available in the UK to treat patients with CTEPH

Bayer’s Adempas now available in the UK to treat patients with CTEPH

Adempas (riociguat) is available in the UK today as the first drug treatment for CTEPH, to treat adult patients with WHO Functional Class (FC) II to III with inoperable or persistent disease to improve exercise capacity. [More]
ATS develops clinical practice guidelines to help clinicians identify, manage patients with sickle cell disease

ATS develops clinical practice guidelines to help clinicians identify, manage patients with sickle cell disease

The American Thoracic Society has developed clinical practice guidelines to help clinicians identify and manage patients with sickle cell disease who are at increased risk for mortality from pulmonary hypertension. [More]
New research uncovers abnormal molecular signaling pathways for kidney failure

New research uncovers abnormal molecular signaling pathways for kidney failure

Prevention and reversal of chronic kidney disease is an urgent public health need. The disease affects 1 in 10 Americans, is debilitating and deadly, and existing drugs, at best, offer only mild delay in progression to end-stage kidney failure. [More]
Researchers identify protein that promotes growth of brain cells damaged by MS

Researchers identify protein that promotes growth of brain cells damaged by MS

Vittorio Gallo, PhD, Director of the Center for Neuroscience Research at Children's National Health System, and other researchers have found a "potentially novel therapeutic target" to reduce the rate of deterioration and to promote growth of brain cells damaged by multiple sclerosis (MS). Current therapies can be effective in patients with relapsing MS, but have little impact in promoting tissue growth. [More]
Novel IRL-1620 compound may be useful in treating Alzheimer's disease

Novel IRL-1620 compound may be useful in treating Alzheimer's disease

The novel compound IRL-1620 may be useful in treating Alzheimer's disease as it has been shown to prevent cognitive impairment and oxidative stress in animal models. This research is being presented at the 2013 American Association of Pharmaceutical Scientists Annual Meeting and Exposition, the world's largest pharmaceutical sciences meeting, in San Antonio, Nov. 10-14. [More]
Opsumit drug receives FDA approval to treat adults with pulmonary arterial hypertension

Opsumit drug receives FDA approval to treat adults with pulmonary arterial hypertension

​The U.S. Food and Drug Administration today approved Opsumit (macitentan), a new drug to treat adults with pulmonary arterial hypertension (PAH), a chronic, progressive and debilitating disease that can lead to death or the need for lung transplantation. [More]
Bayer HealthCare receives FDA approval for Adempas tablets

Bayer HealthCare receives FDA approval for Adempas tablets

Bayer HealthCare announced today that the United States Food and Drug Administration has approved Adempas (riociguat) tablets for: (i) the treatment of adults with persistent/recurrent chronic thromboembolic pulmonary hypertension (WHO Group 4) after surgical treatment or inoperable CTEPH to improve exercise capacity and WHO functional class; and (ii) the treatment of adults with pulmonary arterial hypertension (WHO Group 1) to improve exercise capacity, improve WHO functional class and delay clinical worsening. [More]
Intracerebral injection of BSC may reduce post-stroke cognitive dysfunction

Intracerebral injection of BSC may reduce post-stroke cognitive dysfunction

​Cognitive deficits following ischemic stroke are common and debilitating, even in the relatively few patients who are treated expeditiously so that clots are removed or dissolved rapidly and cerebral blood flow restored. [More]
Advertisement
Advertisement